145 related articles for article (PubMed ID: 27012497)
1. Estrogen receptor alpha transcriptionally activates casein kinase 2 alpha: A pivotal regulator of promyelocytic leukaemia protein (PML) and AKT in oncogenesis.
Das N; Datta N; Chatterjee U; Ghosh MK
Cell Signal; 2016 Jun; 28(6):675-87. PubMed ID: 27012497
[TBL] [Abstract][Full Text] [Related]
2. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
Kuo HY; Huang YS; Tseng CH; Chen YC; Chang YW; Shih HM; Wu CW
Cell Cycle; 2014; 13(19):3132-42. PubMed ID: 25486572
[TBL] [Abstract][Full Text] [Related]
3. Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer.
Chatterjee A; Chatterjee U; Ghosh MK
Cell Death Dis; 2013 Mar; 4(3):e543. PubMed ID: 23492774
[TBL] [Abstract][Full Text] [Related]
4. Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.
Hung MS; Lin YC; Mao JH; Kim IJ; Xu Z; Yang CT; Jablons DM; You L
PLoS One; 2010 Jul; 5(7):e11418. PubMed ID: 20625391
[TBL] [Abstract][Full Text] [Related]
5. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
6. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
7. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
8. Promyelocytic Leukemia (PML) gene regulation: implication towards curbing oncogenesis.
Datta N; Islam S; Chatterjee U; Chatterjee S; Panda CK; Ghosh MK
Cell Death Dis; 2019 Sep; 10(9):656. PubMed ID: 31506431
[TBL] [Abstract][Full Text] [Related]
9. The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT.
Wang X; Yang Z; Zhang H; Ding L; Li X; Zhu C; Zheng Y; Ye Q
Biochim Biophys Acta; 2008 Jun; 1783(6):1220-8. PubMed ID: 18302941
[TBL] [Abstract][Full Text] [Related]
10. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
[TBL] [Abstract][Full Text] [Related]
11. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.
Hao L; Rizzo P; Osipo C; Pannuti A; Wyatt D; Cheung LW; Sonenshein G; Osborne BA; Miele L
Oncogene; 2010 Jan; 29(2):201-13. PubMed ID: 19838210
[TBL] [Abstract][Full Text] [Related]
12. CK2 and PML: regulating the regulator.
Lallemand-Breitenbach V; de Thé H
Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
14. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
15. NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer.
Elsarraj HS; Valdez KE; Hong Y; Grimm SL; Ricci LR; Fan F; Tawfik O; May L; Cusick T; Inciardi M; Redick M; Gatewood J; Winblad O; Hilsenbeck S; Edwards DP; Hagan CR; Godwin AK; Fabian C; Behbod F
Cancer Res; 2017 Jul; 77(14):3802-3813. PubMed ID: 28515148
[TBL] [Abstract][Full Text] [Related]
16. The PML isoform IV is a negative regulator of nuclear EGFR's transcriptional activity in lung cancer.
Kuo HY; Chen YC; Chang HY; Jeng JC; Lin EH; Pan CM; Chang YW; Wang ML; Chou YT; Shih HM; Wu CW
Carcinogenesis; 2013 Aug; 34(8):1708-16. PubMed ID: 23563092
[TBL] [Abstract][Full Text] [Related]
17. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
18. ERalpha signaling through slug regulates E-cadherin and EMT.
Ye Y; Xiao Y; Wang W; Yearsley K; Gao JX; Shetuni B; Barsky SH
Oncogene; 2010 Mar; 29(10):1451-62. PubMed ID: 20101232
[TBL] [Abstract][Full Text] [Related]
19. The DEAD box protein p68: a crucial regulator of AKT/FOXO3a signaling axis in oncogenesis.
Sarkar M; Khare V; Guturi KK; Das N; Ghosh MK
Oncogene; 2015 Nov; 34(47):5843-56. PubMed ID: 25745998
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells.
Bonofiglio D; Gabriele S; Aquila S; Catalano S; Gentile M; Middea E; Giordano F; Andò S
Clin Cancer Res; 2005 Sep; 11(17):6139-47. PubMed ID: 16144913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
